Literature DB >> 14702180

The prognostic significance of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in breast carcinomas.

H Li1, Z Suo, Y Zhang, B Risberg, M G Karlsson, K Villman, J M Nesland.   

Abstract

Thymidine phosphorylase (TP), thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) have been indicated as possible predictive markers for epithelial malignancies. All these three enzymes are actively involved in 5-FU metabolism. In this report, we investigated mRNA expression of these factors with real-time quantitative PCR in a series of 86 micro-selected breast carcinomas and 8 micro-selected tumour-adjacent normal breast epithelial specimens. Highly variable mRNA expressions of these factors were observed in both normal and cancerous samples. TP and TS mRNA expressions in breast carcinomas were elevated, but only TS mRNA expression showed a trend for statistical difference, compared with the expression in normal breast epithelial samples. Although the DPD mRNA expression range in tumours was also elevated, the average mean was reduced in tumours compared to that in normal samples. No association between mRNA expressions of TP, TS and DPD and clinicopathological features such as histological grade, tumour size, node status, S-phase fraction, ploidy, and clinical stage was found. A negative association between DPD mRNA expression and age was, however, revealed. Ten-year follow-up analysis showed no association between TP and DPD mRNA expression and clinical outcome. An high level of TS mRNA expression, however, was associated with a shorter clinical survival, indicating its potential role as a clinical marker in breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14702180     DOI: 10.14670/HH-19.129

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  7 in total

Review 1.  Targeting nuclear thymidylate biosynthesis.

Authors:  James Chon; Patrick J Stover; Martha S Field
Journal:  Mol Aspects Med       Date:  2016-11-19

2.  Relative level of thymidylate synthase mRNA expression in primary tumors and normal tissues predicts survival of patients with oral tongue squamous cell carcinoma.

Authors:  Ryuji Yasumatsu; Torahiko Nakashima; Takahiro Wakasaki; Toranoshin Ayada; Hideki Kadota; Muneyuki Masuda; Satoshi Toh; Hideki Shiratsuchi; Shizuo Komune
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-08-21       Impact factor: 2.503

3.  Cytogenetic characterization of HB2 epithelial cells from the human breast.

Authors:  Fabio Caradonna; Claudio Luparello
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-08-27       Impact factor: 2.416

Review 4.  First-line treatment strategies for elderly patients with metastatic colorectal cancer.

Authors:  Hielke J Meulenbeld; Geert-Jan Creemers
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

5.  Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.

Authors:  S Lee; Y H Park; K H Kim; E Y Cho; Y C Ahn; K Kim; Y-M Shim; J S Ahn; K Park; Y-H Im
Journal:  Br J Cancer       Date:  2010-08-10       Impact factor: 7.640

6.  Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysis.

Authors:  Anna Lisa Tedeschi; Zohreh Eslami; Evgenia Garoufalis; Ramy R Saleh; Atilla Omeroglu; Gulbeyaz Altinel; Maria Ait-Tihyaty; Bertrand Jean-Claude; Catalin Mihalcioiu
Journal:  Onco Targets Ther       Date:  2015-04-21       Impact factor: 4.147

Review 7.  The dual role of thymidine phosphorylase in cancer development and chemotherapy.

Authors:  Annelies Bronckaers; Federico Gago; Jan Balzarini; Sandra Liekens
Journal:  Med Res Rev       Date:  2009-11       Impact factor: 12.944

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.